Welcome to Anagrammer Crossword Genius! Keep reading below to see if adfal is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on adfal.
adfal
Searching in Crosswords ...
The answer ADFAL has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word ADFAL is NOT valid in any word game. (Sorry, you cannot play ADFAL in Scrabble, Words With Friends etc)
There are 5 letters in ADFAL ( A1D2F4L1 )
To search all scrabble anagrams of ADFAL, to go: ADFAL
Rearrange the letters in ADFAL and see some winning combinations
4 letters out of ADFAL
Searching in Dictionaries ...
Definitions of adfal in various dictionaries:
No definitions found
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
| Adfal might refer to |
|---|
| Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. In rheumatoid arthritis, adalimumab has a response rate similar to methotrexate, and in combination, it nearly doubles the response rate of methotrexate alone.Adalimumab is a TNF-inhibiting, anti-inflammatory, biologic medication. It binds to tumor necrosis factor-alpha (TNFα), which normally binds to TNFα receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFα, adalimumab reduces this inflammatory response. Because TNFα is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections. * Humira costs approximately $4370 per month (2017). From 2012 until the US patent expiry in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had $16 billion of global sales. In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira's U.S. patent expired in 2016.* |